March 30, 2022
Dear Advocate,
At AVAC, we’ve been calling for coordinated planning to introduce and rollout new prevention products, while expanding access to existing options. We’ve said that these efforts must move much faster than they have in the past, and learn from the
lessons of rolling out oral PrEP. So what matters right now for rolling out the
Dapivirine Vaginal Ring and
injectable cabotegravir as additional PrEP options? Find out in our
latest episode of Px Pulse!
Until now, daily oral PrEP, first approved in 2012, has been the only drug-based strategy for HIV prevention. So now it’s time to take the next steps to deliver these new options.
In this episode of Px Pulse,
Linda-Gail Bekker from South Africa’s Desmond Tutu Health Foundation and Lillian Mworeko from the
International Community of Women Living with HIV East Africa (ICWEA) join host Jeanne Baron and AVAC’s Executive Director Mitchell Warren to discuss innovative models for scale-up and delivery. Taking the right steps now could mean HIV prevention options fulfill their life-saving, epidemic-ending potential, and to do so requires working faster and more efficiently than ever before. We dive into what lessons the field has learned, what’s still off-track, and the steps advocates, policy makers, drug makers and funders should each take right now to turn efficacious options into effective choices.
For the full podcast episode, highlights, and the archive of previous episodes, visit
avac.org/px-pulse. And subscribe on
Apple Podcasts,
Spotify or wherever you get your podcasts!
Best,
AVAC
